Skip to main content

Articles

Conference Highlights ASH

JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis

Increasing Emphasis on Costs in the Management of Patients with Hematologic Cancers

Rituximab Maintenance Extends Remission in Follicular Lymphoma, but Overall Survival Unaffected

Surveillance Scanning in Transformed Indolent Lymphoma of Limited Clinical Benefit

PI3K Inhibitors Main Focus of Drug Pipeline for Lymphoma

Promise of Genomic Sequencing for Clinical Decision-Making in Hematopoietic Cancers

Multiple Myeloma, Oncology

Myeloma Drug Arsenal Expanding to New Classes

Multiple Myeloma, Oncology

Lenalidomide Maintenance in Transplant-Eligible Myeloma Population Still Debated

Multiple Myeloma, Oncology

FIRST Trial Shows Value for Continued Use of Lenalidomide in Transplant-Ineligible Patients with Newly Diagnosed Myeloma

Leukemia, Oncology

Nilotinib Sustains Deeper Molecular Response versus Imatinib in Patients with Ph+ CML

Page 158 of 244
Results 1571 - 1580 of 2436